Bavarian Nordic Announces Initiation of Clinical Trial with Novel Cancer Immunotherapy Targeting Brachyury in … – GlobeNewswire (press release)
|
Bavarian Nordic Announces Initiation of Clinical Trial with Novel Cancer Immunotherapy Targeting Brachyury in …
GlobeNewswire (press release) COPENHAGEN, Denmark, January 19, 2018 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the initiation of a clinical trial of BN-Brachyury, a novel cancer immunotherapy candidate designed to target brachyury, a key driver of cancer … |
